74 related articles for article (PubMed ID: 24251463)
1. Molecular dynamics and docking simulation of a natural variant of Activated Protein C with impaired protease activity: implications for integrin-mediated antiseptic function.
D'Ursi P; Orro A; Morra G; Moscatelli M; Trombetti G; Milanesi L; Rovida E
J Biomol Struct Dyn; 2015; 33(1):85-92. PubMed ID: 24251463
[TBL] [Abstract][Full Text] [Related]
2. Involvement of Lys 62(217) and Lys 63(218) of human anticoagulant protein C in heparin stimulation of inhibition by the protein C inhibitor.
Shen L; Villoutreix BO; Dahlbäck B
Thromb Haemost; 1999 Jul; 82(1):72-9. PubMed ID: 10456457
[TBL] [Abstract][Full Text] [Related]
3. Contribution of basic residues of the 70-80-loop to heparin binding and anticoagulant function of activated protein C.
Yang L; Manithody C; Rezaie AR
Biochemistry; 2002 May; 41(19):6149-57. PubMed ID: 11994010
[TBL] [Abstract][Full Text] [Related]
4. Interspecies loop grafting in the protease domain of human protein C yielding enhanced catalytic and anticoagulant activity.
Shen L; Villoutreix BO; Dahlbäck B
Thromb Haemost; 1999 Sep; 82(3):1078-87. PubMed ID: 10494767
[TBL] [Abstract][Full Text] [Related]
5. Basic residues in the 37-loop of activated protein C modulate inhibition by protein C inhibitor but not by alpha(1)-antitrypsin.
Glasscock LN; Gerlitz B; Cooper ST; Grinnell BW; Church FC
Biochim Biophys Acta; 2003 Jun; 1649(1):106-17. PubMed ID: 12818196
[TBL] [Abstract][Full Text] [Related]
6. Mapping of heparin/heparan sulfate binding sites on αvβ3 integrin by molecular docking.
Ballut L; Sapay N; Chautard E; Imberty A; Ricard-Blum S
J Mol Recognit; 2013 Feb; 26(2):76-85. PubMed ID: 23334915
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel small molecule inhibitors of activated protein C.
Sperandio O; Wildhagen KC; Schrijver R; Wielders S; Villoutreix BO; Nicolaes GA
Thromb Res; 2014 Jun; 133(6):1105-14. PubMed ID: 24513148
[TBL] [Abstract][Full Text] [Related]
8. Molecular Insights and Functional Consequences of the Interaction of Heme with Activated Protein C.
Hopp MT; Alhanafi N; Paul George AA; Hamedani NS; Biswas A; Oldenburg J; Pötzsch B; Imhof D
Antioxid Redox Signal; 2021 Jan; 34(1):32-48. PubMed ID: 32705892
[No Abstract] [Full Text] [Related]
9. Contribution of basic residues of the D and H helices in heparin binding to protein C inhibitor.
Neese LL; Wolfe CA; Church FC
Arch Biochem Biophys; 1998 Jul; 355(1):101-8. PubMed ID: 9647672
[TBL] [Abstract][Full Text] [Related]
10. The heparin binding site of protein C inhibitor is protease-dependent.
Li W; Huntington JA
J Biol Chem; 2008 Dec; 283(51):36039-45. PubMed ID: 18974053
[TBL] [Abstract][Full Text] [Related]
11. Engineering the proteolytic specificity of activated protein C improves its pharmacological properties.
Berg DT; Gerlitz B; Shang J; Smith T; Santa P; Richardson MA; Kurz KD; Grinnell BW; Mace K; Jones BE
Proc Natl Acad Sci U S A; 2003 Apr; 100(8):4423-8. PubMed ID: 12671072
[TBL] [Abstract][Full Text] [Related]
12. Functional consequences of mutations in amino acid residues that stabilize calcium binding to the first epidermal growth factor homology domain of human protein C.
Geng JP; Cheng CH; Castellino FJ
Thromb Haemost; 1996 Nov; 76(5):720-8. PubMed ID: 8950780
[TBL] [Abstract][Full Text] [Related]
13. The role of autolysis loop in determining the specificity of coagulation proteases.
Yang L; Manithody C; Rezaie AR
Braz J Med Biol Res; 2007 Aug; 40(8):1055-64. PubMed ID: 17665041
[TBL] [Abstract][Full Text] [Related]
14. Protein C and its inhibitor in malignancy.
Suzuki K; Hayashi T
Semin Thromb Hemost; 2007 Oct; 33(7):667-72. PubMed ID: 18000793
[TBL] [Abstract][Full Text] [Related]
15. Possible mechanisms contributing to oxidative inactivation of activated protein C: molecular dynamics study.
Nalian A; Iakhiaev AV
Thromb Haemost; 2008 Jul; 100(1):18-25. PubMed ID: 18612533
[TBL] [Abstract][Full Text] [Related]
16. Structural analysis of the N-terminal fragment of the antiangiogenic protein endostatin: a molecular dynamics study.
Torres PH; Sousa GL; Pascutti PG
Proteins; 2011 Sep; 79(9):2684-92. PubMed ID: 21769939
[TBL] [Abstract][Full Text] [Related]
17. Hepatocyte growth factor activator (HGFA): its regulation by protein C inhibitor.
Suzuki K
FEBS J; 2010 May; 277(10):2223-9. PubMed ID: 20402764
[TBL] [Abstract][Full Text] [Related]
18. In silico profiling and structural insights of missense mutations in RET protein kinase domain by molecular dynamics and docking approach.
George Priya Doss C; Rajith B; Chakraboty C; Balaji V; Magesh R; Gowthami B; Menon S; Swati M; Trivedi M; Paul J; Vasan R; Das M
Mol Biosyst; 2014 Mar; 10(3):421-36. PubMed ID: 24336963
[TBL] [Abstract][Full Text] [Related]
19. Binding investigation of integrin alphavbeta3 with its inhibitors by SPR technology and molecular docking simulation.
Liu Y; Pan Y; Xu Y
J Biomol Screen; 2010 Feb; 15(2):131-7. PubMed ID: 20086207
[TBL] [Abstract][Full Text] [Related]
20. High Affinity vs. Native Fibronectin in the Modulation of αvβ3 Integrin Conformational Dynamics: Insights from Computational Analyses and Implications for Molecular Design.
Paladino A; Civera M; Belvisi L; Colombo G
PLoS Comput Biol; 2017 Jan; 13(1):e1005334. PubMed ID: 28114375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
